Journal article
The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial
Susan R Davis, Penelope J Robinson, Fiona Jane, Shane White, Kristy A Brown, Sofie Piessens, Andrew Edwards, Jane McNeilage, Jillian Woinarski, Mitchell Chipman, Robin J Bell
CLINICAL ENDOCRINOLOGY | WILEY | Published : 2018
DOI: 10.1111/cen.13830
Abstract
BACKGROUND: We investigated whether metformin prevents tamoxifen-induced endometrial changes and insulin resistance (IR) after a diagnosis of breast cancer. METHODS: This was a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. Postmenopausal women with hormone receptor-positive breast cancer taking tamoxifen were randomly allocated to metformin 850 mg or identical placebo, twice daily, for 52 weeks. Outcome measures included double endometrial thickness (ET) measured by transvaginal ultrasound, fasting insulin, glucose and IR estimated by the homeostasis model of assessment (HOMA-IR). RESULTS: A total of 112 women were screened and 102 randomized. Results are..
View full abstractGrants
Awarded by Australian National Health and Medical Research Council of Australia
Funding Acknowledgements
This study was funded by an Australian National Health and Medical Research Council of Australia Project Grant No. 1061800; SRD holds an NHMRC Research Fellowship Grant No. 1135843.